IPP Bureau
Briefs: Sun Pharmaceutical Industries and Biocon Biologics
By IPP Bureau - November 04, 2024
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
By IPP Bureau - November 02, 2024
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
MilliporeSigma invests US$ 76 million to expand ADC manufacturing in North America
By IPP Bureau - November 02, 2024
Reinforces position as first commercially approved contract development and manufacturing organization (CDMO) for ADCs in North America
UPM, Selenis and Bormioli Pharma introduce the world's first pharmaceutical bottle partially made with wood-based plastics
By IPP Bureau - November 02, 2024
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
Lupin to develop inhalers with near-zero global warming potential propellants
By IPP Bureau - November 01, 2024
Lupin's R&D teams are working on products with a near-zero global warming potential propellant
AbbVie to acquire Aliada Therapeutics
By IPP Bureau - November 01, 2024
Strengthening focus in Alzheimer's disease and neuroscience pipeline
AstraZeneca China President currently under investigation
By IPP Bureau - November 01, 2024
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
By IPP Bureau - November 01, 2024
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
By IPP Bureau - November 01, 2024
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Supriya Lifescience reports 19% revenue increase in Q2 FY25
By IPP Bureau - November 01, 2024
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
PM Modi launches and inaugurates Rs. 12,850 crore health projects at AIIA, New Delhi
By IPP Bureau - October 30, 2024
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
MRP of anti-cancer drugs to come down due to custom duty exemption and GST rate reduction
By IPP Bureau - October 30, 2024
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
GlaxoSmithKline Pharmaceuticals Q2 FY25 revenue crosses Rs. 1,000 Cr
By IPP Bureau - October 30, 2024
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Prime Minister launches expansion of health coverage for citizens of and above 70 years
By IPP Bureau - October 30, 2024
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
